AKT1 and neoplasm: Numerous studies have reported that Mcl-1 protein levels are inhibited by targeting PI3K/Akt and/or mTOR pathways using specific inhibitors, leading to increased tumor cell killing in both in vitro and in vivo models [51, 52].